Daewoong Pharmaceutical
Daewoong Pharmaceutical Co., Ltd., commonly referred to as Daewoong, is a leading South Korean pharmaceutical company headquartered in Incheon, South Korea. Established in 1945, Daewoong has made significant strides in the pharmaceutical industry, focusing on research and development, manufacturing, and marketing of innovative medicines. The company operates extensively across Asia, Europe, and the Americas, with a diverse portfolio that includes prescription drugs, over-the-counter products, and biopharmaceuticals. Notable for its commitment to innovation, Daewoong has developed unique therapies in areas such as gastroenterology, neurology, and endocrinology. With a strong market position, Daewoong has achieved several milestones, including the successful launch of its biosimilar products, which have garnered recognition for their quality and efficacy. As a forward-thinking organisation, Daewoong Pharmaceutical continues to contribute to global health advancements.
DitchCarbon Score
How does Daewoong Pharmaceutical's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Medical Device Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Daewoong Pharmaceutical's score of 50 is higher than 97% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Daewoong Pharmaceutical's reported carbon emissions
In 2023, Daewoong Pharmaceutical reported total carbon emissions of approximately 34,706,000 kg CO2e, comprising 10,184,000 kg CO2e from Scope 1, 24,522,000 kg CO2e from Scope 2, and 2,092,000 kg CO2e from Scope 3 emissions. The company has shown a commitment to reducing its carbon footprint, although specific reduction targets or initiatives have not been disclosed. Over the years, Daewoong's emissions have fluctuated, with a notable increase in Scope 1 emissions from 4,119,000 kg CO2e in 2017 to 10,184,000 kg CO2e in 2023. Scope 2 emissions also rose from 61,357,000 kg CO2e in 2017 to 24,522,000 kg CO2e in 2023, while Scope 3 emissions peaked at 2,830,442,000 kg CO2e in 2022, indicating a significant impact from the use of sold products. Despite the lack of formal reduction targets, Daewoong Pharmaceutical's ongoing efforts to monitor and report its emissions reflect a growing awareness of climate responsibilities within the pharmaceutical industry. The company continues to engage in practices aimed at sustainability, aligning with global trends towards reducing greenhouse gas emissions.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
Add to project| 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|
| Scope 1 | 4,119,000 | 0,000,000 | 0,000,000 | 0,000,000 | 0,000,000 | 00,000,000 | 00,000,000 | 0,000,000 |
| Scope 2 | 61,357,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 |
| Scope 3 | 70,501,000 | 00,000,000 | 00,000,000 | - | 0,000,000 | 0,000,000 | 0,000,000 | 0,000,000 |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Daewoong Pharmaceutical is not committed to any reduction initiatives we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
